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Abstract 
Compounds designed to display polypharmacology may have utility in treating complex diseases, where activity at 
multiple targets is required to produce a clinical effect. In particular, suitable compounds may be useful in treating 
neurodegenerative diseases by promoting neuronal survival in a synergistic manner via their multi-target activity at 
the adenosine  A1 and  A2A receptors  (A1R and  A2AR) and phosphodiesterase 10A (PDE10A), which modulate intracel-
lular cAMP levels. Hence, in this work we describe a computational method for the design of synthetically feasible 
ligands that bind to  A1 and  A2A receptors and inhibit phosphodiesterase 10A (PDE10A), involving a retrosynthetic 
approach employing in silico target prediction and docking, which may be generally applicable to multi-target 
compound design at several target classes. This approach has identified 2-aminopyridine-3-carbonitriles as the first 
multi-target ligands at  A1R,  A2AR and PDE10A, by showing agreement between the ligand and structure based predic-
tions at these targets. The series were synthesized via an efficient one-pot scheme and validated pharmacologically as 
 A1R/A2AR–PDE10A ligands, with  IC50 values of 2.4–10.0 μM at PDE10A and  Ki values of 34–294 nM at  A1R and/or  A2AR. 
Furthermore, selectivity profiling of the synthesized 2-amino-pyridin-3-carbonitriles against other subtypes of both 
protein families showed that the multi-target ligand 8 exhibited a minimum of twofold selectivity over all tested off-
targets. In addition, both compounds 8 and 16 exhibited the desired multi-target profile, which could be considered 
for further functional efficacy assessment, analog modification for the improvement of selectivity towards  A1R,  A2AR 
and PDE10A collectively, and evaluation of their potential synergy in modulating cAMP levels.
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Background
Neurodegeneration involves the progressive loss of the 
structure and function of neurons, which is common 
in Parkinson’s, Huntington’s disease and schizophrenia 
[1]. Recently, there has been substantial interest in the 
search for alternative non-dopamine (non-DA) based 
approaches for the treatment of neurodegenerative dis-
eases, as the classical DA-based approaches have long 
been associated with many undesirable side effects such 
as dyskinesia, hallucinations, and on/off effects [2]. Given 
that the adenosine neuromodulation system (via the 
adenosine  A1 and  A2A receptors) has been identified as 
a key target for the management of neurodegenerative 
diseases, this qualifies its targeting as a potential prom-
ising non-DA based treatment approach [3, 4]. Indeed, 
modulation of cAMP levels has proven to have benefits 
in neuronal survival in an adenosine receptor-depend-
ent manner [5]. In addition, recent findings suggest that 
phosphodiesterase 10A (PDE10A) also plays a role in 
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neurodegenerative diseases such as Parkinson’s, Hun-
tington’s disease, and schizophrenia [6–8]. Inhibition of 
PDE10A resulting in maintenance of elevated intracellu-
lar cAMP concentrations, has been suggested to be effec-
tive in the treatment of these diseases. Thus multi-target 
ligands that bind to different adenosine receptors sub-
types  (A1 and  A2A receptors) while simultaneously inhibit 
PDE10A might be synergistic in modulating cAMP lev-
els, which is of therapeutic potential for neurodegenera-
tive diseases [9–11].
Conceptually, multi-target drugs work by creating a 
combination effect on multiple targets in the biological 
network simultaneously, which may (through e.g. syner-
gistic effects) decrease the therapeutic dose required, thus 
increasing therapeutic efficacy, preventing drug resistance, 
and reducing target-related adverse effects [12–14]. Also, 
another advantage of multi-target drugs over other types 
of treatments such as combination therapies, is a reduced 
likelihood of drug–drug interactions [15, 16].
However, it remains a challenging task for medicinal 
chemists to design drugs with a specific multi-target pro-
file and to achieve selectivity for specific targets over off-
target effects with suitable pharmacokinetic properties 
[17, 18]. In fact, the field of multi-target drug design has 
recently become an active field of research in the phar-
maceutical industry, where around 20 designed multi-
target drugs have either reached advanced development 
stages or are already approved [14, 19, 20].
In particular, for Central Nervous System (CNS) dis-
eases, there has been growing interest in exploiting the 
multi-target profiles of existing compounds to investigate 
their potential applicability as drugs. For example, multi-
target profiles of drugs and drug candidates affecting the 
dopaminergic system have been investigated. Examples 
include Aripiprazole, Amitriptyline, Chlorpromazine, and 
Clozapine [21]. In addition, various multi-target based 
virtual screening protocols for multi-target drug design 
have been developed [13, 22–24]. Examples of ligand-
based protocols include in silico target prediction and 
Chemogenomic and pharmacophore-based approaches, 
which resulted in the discovery of CNS drugs with multi-
target combinations such as MAO-A/MAO-B/AChE/
BuChE, AChE/BuChE, and  H3-R/HMT/AChE/BuChE 
[21–24]. Structure-based approaches such as docking and 
molecular dynamics calculations have also been employed 
for the discovery of new multi-target ligands such as 
BuChE inhibitors/hCB2R and MAO-A/MAO-B/AChE/
BuChE ligands to treat neurodegenerative diseases [25].
In this work, we offer a computational strategy for 
designing synthetically feasible ligands that bind to  A1R 
and  A2AR, and inhibit PDE10A—a novel multi-target 
combination of G protein-coupled receptors (GPCRs) 
and an enzyme, which has not, to our knowledge, been 
previously exploited. The designed ligands with this 
multi-target combination are intended as starting points 
for future development of multi-target drugs treating 
neurodegenerative diseases. It should be noted here that 
in the current study we only consider affinity of ligands to 
the above receptors, which we also experimentally vali-
date as outlined below. However, for therapeutically rel-
evant purposes also functional effects and optimization 
of selectivity towards  A1R,  A2AR and PDE10A need to be 
considered, which will be the area of a future study.
The workflow of the current study is shown in Fig.  1. 
Starting with a focused chemical space consisting of 
known actives against  A1R,  A2AR and PDE10A, new 
synthetically feasible compounds were established via 
RECAP (Retrosynthetic Combinatorial Analysis Proce-
dure) [26, 27], which fragments molecules at pre-defined 
bonds and recombines them in a combinatorial manner, 
and were then evaluated in silico, using target prediction 
and ligand/protein docking. Compounds with favorable 
assessments in both steps were carried forward for sub-
structural analysis. This analysis identified compound 
series with the highest frequency of prediction as multi-
target ligands against the desired set of targets, which is 
of advantage from the practical side, given their synthetic 
accessibility via a common synthetic route.
 A series of 2-aminopyridine-3-carbonitriles were 
selected for prospective validation of the pipeline, a series 
which was synthetically accessible via a one pot synthetic 
scheme i.e. providing products with the desired proper-
ties: cost-effective, synthetically efficient and available in 
a timely fashion [28, 29].
Subsequently the synthesized compounds were experi-
mentally tested and confirmed as  A1R/A2AR–PDE10A 
multi-target ligands. Selectivity against other subtypes 
of both protein families confirmed the pharmacologi-
cal profile of the compound series, and structure activ-
ity relationships (SAR) were also deduced. Hence, in 
this work we report a successful computational strat-
egy, which allowed the discovery of the first  A1R/
A2AR–PDE10A multi-target ligands. The novel  A1R/
A2AR–PDE10A ligands are sought to display a combina-
tion effect in modulating the  A1R,  A2AR, and PDE10A 
targets simultaneously similar to that of combination 
compounds of Adenosine receptors and PDEs, reported 
by Rickles et  al., which were synergistic in modulating 
cAMP levels [10].
Results and discussion
Design of synthetically feasible  A1R/A2AR–PDE10A 
multi‑target ligands
Human enzyme and receptor data were extracted from 
ChEMBL 20 [30]. Substructure analysis of  A1R,  A2AR 
ligands and PDE10A inhibitors with  Ki and  IC50 values 
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less than or equal to 1  µM revealed that the most fre-
quently occurring common heterocycles among the 
actives against the three target classes were pyridine, 
pyrimidine, piperazine, and 1H-pyrazole (Additional 
file 1: Figure S1). Subsequently,  A1R (2104),  A2AR (2489) 
and PDE10A inhibitors (679) containing those frequent 
heterocycles were subjected to RECAP analysis/synthe-
sis in MOE (see Methods for details) [26]. As a result, 
458,839 (potentially) synthetically accessible ligands were 
formed in silico. This list of candidates was filtered to 
those retaining the common heterocycles (listed above), 
in order to create a focused chemical space characteristic 
Fig. 1 The computational strategy for rational design of  A1R/A2AR–PDE10A multi-target ligands started with a focused chemical space consisting of 
known actives of  A1R,  A2AR and PDE10A, and formed new synthetically feasible compounds which were subjected to target prediction and docking 
for synthesis and pharmacological evaluation
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of  A1R,  A2AR and PDE10A (with the simultaneous trade-
off of reduced novelty), giving rise to 22,233 compounds.
Target prediction of the designed RECAP library
To assess the likelihood of active compounds against 
 A1R,  A2AR and PDE10A, PIDGIN 1.0 (Prediction includ-
ing Inactivity), a tool which uses ECFP 4 circular Mor-
gan fingerprints and trained on ChEMBL actives and 
PubChem inactives, was used to perform in silico target 
prediction for the focused RECAP library (22,233 com-
pounds) [24]. Subsequent enrichment analysis of the 
predictions was done using an estimation score, average 
ratio as developed by Liggi et al. [31] and via Chi square 
test [32]. For targets to be considered as enriched accord-
ing to these methods, the estimation score and the Chi 
square test p value should be less than or equal to 0.01 
and 0.05, respectively. Hence, upon analyzing the enrich-
ment parameters for the  A1R,  A2AR and PDE10A targets 
that were predicted for the focused RECAP library (Addi-
tional file 1: Figure S2), the three targets were predicted 
with an estimation score equal to 0 (enriched) as well as 
average ratios less than 0.1 (enriched) with Chi squared p 
values < 0.005. The percentage of RECAP compounds of 
the focused library that were predicted as actives against 
the  A1R,  A2AR and PDE10A targets were 51.1, 52.8, and 
24.5% respectively. These numbers are relatively high, 
which however is understandable given that the input to 
the RECAP analysis consisted of experimentally estab-
lished known ligands of the above protein targets.
Docking of the compounds predicted as  A1R/A2AR–PDE10A 
multi‑target ligands
In the next step docking and further substructure analy-
sis were performed on compounds of the focused RECAP 
library, which were predicted as  A1R/A2AR–PDE10A 
multi-target ligands from the ligand-based side in the 
previous step. 2563 compounds were predicted as actives 
against the three desired targets, and they were subse-
quently docked against a high resolution (1.8 Å)  A2AR 
protein crystal structure (PDB  ID: 4EIY) [33] its corre-
sponding  A1R homology model (see Methods for details), 
and PDE10A (PDB ID: 4DDL) [34].
Compounds which were carried forward to substruc-
tural analysis were selected when their docking score 
gave a value less than a pre-determined cut-off value 
computed from the docking scores. This cut-off value 
was evaluated as the docking score with the best F meas-
ure statistic obtained by docking a set of known actives 
and inactives against the protein crystal structures and 
the homology model (see Methods for details).
As a result, a distribution of RECAP compounds that 
were favorable as multi-target ligands by target pre-
diction and docking was obtained, where 62.47% of 
the RECAP compounds that were predicted as  A1R/
A2AR–PDE10A multi-target ligands and docked against 
PDE10A exhibited docking scores lower than −  6.49 
(the threshold of the best F measure discriminating 
between actives and inactives for known ligands). Out 
of the RECAP compounds which displayed docking 
scores lower than −  6.49 against PDE10A, 48.89 and 
35.23% displayed docking scores lower than −  7.26 and 
− 8.49 against  A1R and  A2AR (the thresholds of the best 
F measures).
Substructure analysis of the compounds predicted as  A1R/
A2AR–PDE10A multi‑target ligands
Substructure analysis was performed on compounds hav-
ing a favorable assessment by target prediction and dock-
ing (i.e. those compounds whose docking scores were 
below the threshold for all three targets). The analysis 
revealed frequently occurring series, which shared the 
same core structure and which are shown in Fig. 2.
The chemical series were identified as [1,2,4]
triazolo[1,5-c]quinazolines (50.4% of all positively pre-
dicted multi-target ligands by in silico target prediction 
as well as docking), imidazo[1,5-a]quinoxalines (14.4%), 
6,7-alkoxyisoquinolines (10.6%), and 2-aminopyridine-
3-carbonitriles (9.2%). These were in addition to various 
compounds containing the common and frequent het-
erocycles identified earlier (15.4%). Each series identified 
Fig. 2 2563 compounds of the focused RECAP library were predicted 
as  A1R/A2AR–PDE10A multi-target ligands, and docked against the 
 A2AR protein crystal structure (PDB ID: 4EIY),  A1R homology model, 
and the PDE10A protein crystal structure (PDB IB: 4DDL), the RECAP 
series which showed an agreement between the ligand-based and 
structure-based predictions were mainly a 6,7-alkoxyisoquinolines b 
[1,2,4] triazolo[1,5-c]quinazolines c 2-aminopyridine-3-carbonitriles d 
imidazo[1,5-a]quinoxalines
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could be considered for synthesis, SAR studies and vali-
dation as  A1R/A2AR–PDE10A multi-target ligands.
Synthesis of novel 2‑aminopyridine‑3‑carbonitriles
Due to both ease of the reaction and anticipated yield, 
a one-pot synthetic scheme was selected for synthe-
sizing one promising series, 2-aminopyridine-3-car-
bonitriles. The design resulted in 25 compounds for 
synthesis of which 21 were novel compounds and four 
(1, 2, 5, and 17) have previously been reported in the lit-
erature [35–38]. Compounds 1–25 were screened against 
PAINs (PAN Assay Interference Compounds) [39] using 
FAFDrug3 [40], and none of the compounds exihibited 
potential PAINs liability. Subsequently, their synthesis 
was performed as shown in Scheme 1, and all products 
were obtained with good yields, ranging from 46 to 85% 
(see Methods for details).
Pharmacological evaluation of novel 
2‑aminopyridine‑3‑carbonitriles
Bioactivity testing was performed using  A1 and  A2A 
human adenosine receptors expressed in transfected 
CHO  (A1) and HeLa  (A2A) cells, as well as AD293 cells 
that were transiently transfected with human PDE10A. 
Table  1 includes the list of synthesized 4,6-substituted 
2-amino-pyridin-3-carbonitriles, along with their  Ki val-
ues against  A1R,  A2AR, and  IC50 values against PDE10A. 
It can be seen that 15 compounds of the 25 synthesized 
2-amino-pyridin-3-carbonitriles exhibited inhibitory 
activity against PDE10A below 10  μM. In addition, 13 
compounds were adenosine receptor binders exhibiting 
selectivity towards  A1R and  A2AR, which has not been 
the case in the previous work reported by Mantri et al., 
where 2-amino-pyridin-3-carbonitriles were promiscu-
ous towards the four adenosine receptor subtypes [36].
Given that the objective of this work is to find com-
pounds displaying specific multi-target activity, com-
pounds 8, 16, 21, and 25 were identified as  A1R/
A2AR–PDE10A multi-target ligands, inhibiting PDE10A 
with  IC50 values of 2.4, 3.2, 10.0, and 5.1 µM respectively, 
and binding to  A1R with  Ki values of 294 and 34  nM 
(compounds 8 and 16, respectively), and to  A2AR with 
 Ki values of 41, 95, and 55 nM (compounds 16, 21, and 
25, respectively). Notably, compound 16 exhibited the 
desired multi-target profile as a PDE10A inhibitor and a 
dual binder to  A2AR and  A1R.
It was previously reported that substituted pyridines 
exhibited PDE inhibitory activity [41, 42], and 2-amino-
pyridin-3-carbonitriles are adenosine receptor ligands 
[36]. In this study we have now identified suitable com-
pounds matching both criteria as  A1R/A2AR–PDE10A 
multi-target ligands, satisfying the original compound 
design objective.
(SAR) structure–activity relationship analysis
The purpose of the SAR analysis was to rationalize the 
variation in activity of the newly discovered  A1R/A2AR–
PDE10A multi-target ligands against PDE10A, given 
that 2-amino-pyridin-3-carbonitriles have been discov-
ered as a novel class of PDE10A inhibitors. Also due to 
the fact that compounds of this substructural class were 
documented as adenosine receptor ligands [36], compu-
tational SAR studies were focused on the PDE10A data, 
where the variation in potency was rationalized in rela-
tion to the physicochemical properties of the compounds 
(which were computed by FAFDrug3, Additional file  1: 
Table S1) [40].
A trend observed repeatedly in several cases was that 
when logP decreased, associated with an increase in 
tPSA, then this led to an improvement in the activity 
against PDE10A. Initial analysis concentrated on com-
pounds 1–4, which have a phenyl substituent at posi-
tion 4 of the pyridine ring. Compound 3 was the most 
potent PDE10A inhibitor with an  IC50 of 2.0 µM, and a 
computed logP of 3.1 and tPSA of 103.9 Å2. Similarly, for 
compounds 5–7 having a phenyl substituent at position 
6 of the pyridine ring, compound 6 was the most potent 
against PDE10A with an  IC50 of 5.7 µM and a computed 
logP of 4.0 and tPSA of 81.2 Å2. For compounds 8–13, 
which have a cyclohexyl ring at position 4 of the pyridine 
ring, compound 12 displayed the most potent PDE10A 
inhibitory activity with an  IC50 of 0.9  µM and a com-
puted logP of 4.7 and tPSA of 90.9 Å2. For compounds 
14–17, with a p-methoxyphenyl substituent at position 4 
of the pyridine ring, compound 16 with the smallest pre-
dicted lipophilicity of 3.1 and tPSA of 85.1 Å2 displayed 
a good PDE10A inhibitory activity with an  IC50 value 
equal to 3.2 µM, yet the most potent compound was 15 
Scheme 1 The one-pot synthetic route followed for the synthesis of novel 4,6-substituted 2-amino-pyridin-3-carbonitriles
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Table 1 Percent inhibition of the synthesized 4,6-substituted 2-amino-pyridin-3-carbonitriles at 10 µM (PDE10A) or  IC50 
(µM) and percentage displacement at 0.1 µM  (A1R and  A2AR), or  Ki
Compound R4 R6
% inhibition at 10 µM (PDE10A)  or IC50 (µM)
% displacement at 0.1 µM (A1R and A2AR) or Ki
A1R A2AR PDE10A
1 394 ± 12 nM 32% 22%
2 142 ± 7 nM 38% 52%
3 12% 8% 2.0 ± 0.2 µM
4 26% 32% 3.6 ± 0.3 µM
5 53% 543 ± 13 nM 28% 
6 12% 1% 5.7 ± 0.3 µM
7 25 ± 2 nM 5% 17% 
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Table 1 continued
8 294 ± 10 nM 50% 2.4 ± 0.2 µM
9 84 ± 8 nM 34% 68% 
10 17% 18% 3.7 ± 0.3 µM
11 16% 11% 1.2 ± 0.1 µM
12 44% 60% 0.9 ± 0.2 µM
13 70 ± 3 nM 49 ± 4 nM 55% 
14 108 ± 6 nM 30% 10% 
15 6% 32% 1.5 ± 0.2 µM
16 34 nM ± 2 nM 41 ± 2 nM 3.2 ± 0.4 µM
17 46% 29% 65% 
18 
 
78 ± 5nM 948 ± 13 nM 38% 
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with an  IC50 value of 1.5 µM and a computed logP of 4.4 
and tPSA of 71.9  Å2. For compounds 19–22, with an 
o-methoxyphenyl substituent at position 4 of the pyri-
dine ring, compound 22 displayed PDE10A inhibitory 
activity with the highest potency  (IC50 value of 5.6 µM), 
and a computed logP of 3.7 and tPSA of 92.2 Å2. Finally 
a similar general trend is observed for the compounds 
23 and 24 with a 4-hydroxyphenyl substituent at posi-
tion 6 of the pyridine ring, where compound 24 was a 
more potent PDE10A inhibitor with an  IC50 of 3.1  µM 
and computed logP of 3.4 and tPSA of 103.2 Å2. Hence, 
it could be deduced that in the majority of the series 
considered, where the substituents on a single position 
is varied, a decrease in computed lipophilicity associ-
ated with an increase in polarity generally improved 
the activity of compounds against PDE10A. This gen-
eral trend can be attributed to the hydrophilic nature of 
the pocket, which favours the interactions between the 
ligand and the PDE10A protein by compounds exhibit-
ing these properties.
Table 1 continued
19 58% 338 ± 12 nM 73% 
20 12% 50% 6.4 ± 0.4 µM
21 38% 95 ± 4 nM 10.0 ± 0.6 µM
22 8% 1% 5.6 ± 0.5 µM
23 2% 10% 4.0 ± 0.3 µM
24 19% 7% 3.1 ± 0.4 µM
25 15% 55 ± 2 nM 5.1 ± 0.4 µM
IC50 values of the 2-aminopyridines-3-carbonitriles were measured for the four phosphodiesterases PDE7A, PDE7B, PDE9A and PDE10A at 10 μM concentration. For 
those compounds that showed percentage inhibition greater than 70% and selectivity against other measured isoenzymes,  IC50 were determined. Calculation of the 
 Ki values at  A1R,  A2AR,  A2BR and  A3R was approximated using the Cheng-Prusoff equation:  Ki = IC50/[1 + (C/KD)], where  IC50 is the concentration of compound that 
displaces the binding of the radioligand by 50%, C is the concentration of radioligand, and  KD is the dissociation constant of each radioligand
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Compound selectivity assessment
The selectivity of compounds 1–25 against the selected 
major off-targets  A2BR,  A3R, PDE7A, PDE7B, and 
PDE9A, was predicted using PIDGIN at a threshold for 
binding greater than or equal to 0.8, and subsequently 
tested experimentally. It is noted here that the  IC50 val-
ues were determined for compounds with % inhibition at 
phosphodiesterases greater than 70%. As shown in Addi-
tional file  1: Table S2, the synthesized compounds are 
mostly inactive against those off-targets except for com-
pounds 16, 17, 21, and 23 that exhibited  IC50 values of 
3.4, 3.5, 15.1 and 1.8 µM against PDE7A, and compounds 
23 and 25, which exhibited  IC50 values of 7.3 and 4.7 µM 
against PDE7B. Remarkably, compound 8 was found 
to exhibit selectivity over all tested off-targets using the 
above criterion, with the lowest selectivity measured 
for PDE7B (of 55% inhibition at 10  µM ligand concen-
tration). This can be compared to the  IC50 value of 8 at 
PDE10A, which is 2.4 μM (indicating approximately two-
fold selectivity for 8).
In general, the experimental results on off-target predic-
tion for the synthesised 4,6-substituted 2-amino-pyridin-
3-carbonitriles 1–25 agree with the predictions generated 
using PIDGIN utilised to bias the compound design 
towards selective compounds such as 8 (Additional file 1: 
Table S2). This compound would serve as a good starting 
point for analog modification to improve the selectivity of 
the synthesized ligands towards PDE10A.
Analysis of the molecular docking studies of the 
synthesized 2‑aminopyridine‑3‑carbonitriles
The synthesized 2-aminopyridine-3-carbonitriles were 
docked against  A2AR (PDB ID: 4EIY),  A1R homology 
model, and PDE10A (PDB  ID: 4DDL). Figure  3 shows 
the common predicted ligand-target interactions for rep-
resentative multi-target ligands of  A1R–PDE10A,  A1R–
A2AR, and  A2AR–PDE10A, namely for compounds 8, 18, 
and 25.
It can be seen that compounds 8 and 25, with  IC50 
values of 2.4 and 5.1  µM respectively, share similarities 
in predicted binding modes, since their pyridine rings 
display π-stacking with  Phe686 and  Phe719 of PDE10A 
(Fig.  3). These are the type of interactions predicted to 
be exhibited by the majority of the synthesized ligands 
from this work, as well as the only existing interactions 
between co-crystallised PDE10A inhibitors discovered 
by fragment screening (PDB  ID: 5C2E, 5C1W, 5C29, 
5C2A ligands with  Ki values of 2, 8, 700, 880, and 4.8 nM, 
respectively) [43]. It is noted that the ligand of 5C2A 
exhibits a considerable selectivity towards PDE10A over 
all the other PDEs (in the range of 100–1000 fold and 
greater over the majority of PDEs, with the least selec-
tivity observed being in the range of 25–100 fold). This 
ligand exhibits only π-stacking interactions with  Phe686 
and  Phe719, similar to the mode of interactions of com-
pound 8 with PDE10A, which is relatively selective over 
all tested PDEs, with the lowest selectivity being meas-
ured for PDE7B (of 55% inhibition at 10  µM ligand 
Fig. 3 Docking studies predicted molecular interactions characteristic of the 4,6-substituted 2-amino-pyridin-3-carbonitriles with the  A2AR protein 
crystal structure (PDB ID: 4EIY),  A1R homology model, and PDE10A protein crystal structure (PDB ID: 4DDL), which are displayed for representa-
tive multi-target ligands with the following combinations: compound 8  (A1R–PDE10A), 18  (A1R–A2AR), and 25  (A2AR–PDE10A): a interactions with 
 A2AR: the overlaid compounds 18 and 25 exhibit H-bonds via amino and carbonitrile groups with  Asn253, and the pyridine rings are π-stacked with 
 Phe168 b interactions with  A1R: the overlaid compounds 8 and 18 exhibit H-bonds via amino and carbonitrile groups with  Asn254, and the pyridine 
rings are π-stacked with  Phe171 c interactions with PDE10A: the overlaid compounds 8 and 25 have the pyridine rings π-stacked with  Phe686 and 
 Phe719. The molecular interactions predicted for the active molecules are consistent with observed interactions between co-crystallised ligands and 
their corresponding protein crystal structures (PDB ID: 4EIY and 4DDL) [33, 34] and the interactions with the  A1R homology model reported in the 
literature [51, 52]
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concentration) and compound 25, which is selective 
against all tested PDEs except PDE7B (Table 1 and Addi-
tional file 1: Table S2). Additional interactions were seen 
in analogs discovered by fragment screening, namely 
hydrogen bonding with  Gln716 and  Tyr683 in the PDE10A 
selectivity pocket (PDB ID: 5C28 and 5C2H with  Ki val-
ues of 2200 and 0.0082 nM respectively). [43] The ligand 
of 5C2H exhibits π-stacking with  Phe686 and  Phe719 and 
hydrogen bonding with  Tyr683 in the PDE10A selectiv-
ity pocket. The 5C2H ligand showed a very high selec-
tivity towards PDE10A, greater than 5000 fold, which 
emphasizes the consideration of compound 8 for analog 
modification to target the selectivity pocket in order to 
improve the folds of selectivity towards PDE10A. In 
addition, hydrogen bonding with  Tyr683 in the PDE10A 
selectivity pocket is also seen in many other highly selec-
tive PDE10A inhibitors reported in the literature [44] 
(PDB ID: 5DH5, [45] 5B4L, [46] with  Ki = 0.23 nM, and 
 IC50  =  0.76  nM respectively), which further highlights 
the importance of analog modification to target the 
PDE10A selectivity pocket.
Moreover, it is noted that compounds 16 and 21 with 
 IC50 values of 3.2 and 10.0  µM respectively (which are 
selective against all tested PDEs except PDE7A, Table  1 
and Additional file 1: Table S2) were predicted to exhibit 
an additional type of interaction, H-bonding with  Gln716 
via their overlaid furan rings at position 6 of the pyridine 
ring (Additional file 1: Figure S3). In fact H-bonding with 
 Gln716 was the only interaction, besides π-stacking with 
 Phe686 and  Phe719, which has been observed in many of 
the highly selective PDE10A ligands reported in the lit-
erature (PDB ID: 4DDL, [34] 3SN7, 3SNL, and 3SNI, [47] 
5DH4 and 5DH5, [45] with  IC50 values of 4.9, 0.7, 0.7, 
11 nM and  Ki = 0.23 nM respectively). As for other type 
of interactions generally exhibited by known PDE10A 
inhibitors such as hydrogen bonding with  Gln726 and 
π-stacking with  Phe729 (PDB  ID: 5EDE) [48], none has 
been predicted for any of the compounds presented in 
this work.
Common predicted binding modes can also be 
observed for the synthesized compounds against the 
adenosine receptors  A2AR and  A1R. Figure 3 displays the 
interactions of two representative compounds 18 and 
25, which exhibit  Ki values of 948 and 55  nM respec-
tively, and these are H-bonding of their pyridine rings 
with  Asn253 and π-stacking of their amino and carboni-
trile groups with  Phe168 of  A2AR. As for  A1R, the overlaid 
compounds 8 and 18, with  Ki values of 294 and 78 nM 
respectively, H-bond via their amino and carbonitrile 
groups with  Asn254, and their pyridine rings are π-stacked 
against  Phe171. It can be observed that the ligand/protein 
interactions predicted for the active compounds against 
the  A2AR are also those seen in the co-crystallised ligand/
protein crystal structures (PDB  ID: 4EIY, [33] 3EML, 
[49] 5IU4, [50] with a  Ki value of 0.8 nM for ZM241385, 
which is the common ligand for the three PDB IDs). Sim-
ilar was the case for the reported interactions with the 
 A1R homology model in the literature (with  IC50 values of 
2.9 and 6.2 nM for the reported ligands predicted to bind 
to the homology model of  A1R) [51, 52].
Generally the compounds exhibited good selectiv-
ity towards  A1R and  A2AR (Table 1 and Additional file 1: 
Table S2) with a nanomolar range of binding affinities. As 
for the selectivity towards PDE10A, it could be improved 
by analog modification of compound 8, which favors the 
hydrogen bonding with  Tyr683 in the PDE10A selectivity 
pocket. In addition, the potency of compounds against 
PDE10A could be optimized in itself, in order to achieve 
therapeutically relevant efficacy.
Computational assessment of CNS permeability
Compounds 8 and 16 exhibited the desired multi-target 
profile by inhibiting PDE10A and binding to  A2AR and/
or  A1R. The physicochemical properties of these com-
pounds were calculated by FAFDrug3 [40], and both 
compounds passed the Lipinski rule of 5 and the CNS 
filter, which takes into consideration the assessment of 
their ability to pass the blood brain barrier (Additional 
file 1: Figure S4) [53]. Hence, while further experimental 
work would be needed to establish the validity of those 
predictions, compounds 8 and 16 may serve as good 
starting points for further functional efficacy assessment 
and selectivity optimization towards PDE10A,  A2AR and/
or  A1R for the subsequent consideration of multi-target 
drug development for the treatment of neurodegenera-
tive diseases.
Conclusions
Here we report a successful computational strategy for 
designing the first  A1R/A2AR–PDE10A multi-target 
ligands as a therapeutic prospect for neurodegenerative 
diseases. A retrosynthetic approach was employed using 
MOE/RECAP, followed by target prediction and dock-
ing of the resulting library against the desired targets. 
We have identified 2-aminopyridine-3-carbonitriles as a 
series that showed agreement between both the ligand- 
and structure-based predictions of activity against  A1R, 
 A2AR and PDE10A. The synthesis of this series via a one-
pot synthetic scheme was pursued experimentally. As a 
result, compounds 8, 16, 21, and 25 were validated as 
 A1R/A2AR–PDE10A multi-target ligands with  IC50 val-
ues of 2.4, 3.2, 10.0, and 5.1  µM against PDE10A, and 
binding to  A1R with  Ki values of 294 and 34 nM (8 and 
16 respectively), and to  A2AR with  Ki values of 41, 95, 
and 55  nM (16, 21, and 25 respectively). Furthermore, 
selectivity profiling of the synthesized 4,6-substituted 
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2-amino-pyridin-3-carbonitriles against other subtypes 
of both protein families showed that the multi-target 
ligand 8 exhibited a minimum of twofold selectivity over 
all tested off-targets. In addition, compounds 8 and 16 
exhibited the desired multi-target profile against  A1R, 
 A2AR and PDE10A, which would serve as good start-
ing points for further functional efficacy assessment and 
analog modification for the improvement of selectiv-
ity. In particular, this comprises investigating the signal 
transduction profiles of these compounds using tech-
niques some of the authors have described before [51], 
as well as evaluating functional effects in cAMP assays 
to determine if these compounds do provide synergistic 
elevations in intracellular cAMP. One specific functional 
profile that would be of high interest and which is likely 
to elevate cAMP levels synergistically via the combina-
tion effect on multiple targets simultaneously, is the  A1R 
antagonist/A2AR agonist, and PDE10A inhibitor.
In summary we have investigated a computational 
approach for the design of multi-target ligands that was 
validated experimentally via synthesis and pharmaco-
logical evaluation of 2-aminopyridine-3-carbonitriles as 
 A1R/A2AR–PDE10A ligands. This approach is generally 
applicable to a wide range of multi-target ligand design 
problems, across disease areas and target families.
Experimental
Selecting reference molecules for the design 
of multi‑target ligands
Using SQL (script provided in Additional file 1), human 
 A1R (2860),  A2AR (3566) ligands and PDE10A inhibitors 
(843) were extracted from the ChEMBL 20 database with 
 Ki and  IC50 values less than or equal to 1  μM respec-
tively, and confidence scores of 8 or 9 [30]. Following 
extraction, the most frequent and common heterocycles 
between  A1,  A2A receptor ligands and PDE10A inhibi-
tors were found by performing substructure analysis on 
each structure using the “Chemistry-> Analyze scaffolds” 
function in DataWarrior 4.2.2 [54]. Analysis of  A1R,  A2AR 
ligands and PDE10A inhibitors identified common and 
frequent heterocycles (pyridine, 1H-pyrazole, pyrimi-
dine and 9H-purine for  A1R and  A2AR), and these were 
extracted from each set using RDKit, 9.1, Python [55]. It 
should be noted that compounds containing 9H-purine 
were also extracted from the original set even though 
this substructure is characteristic of  A1R and  A2AR only, 
since it is structurally similar to the common and fre-
quent heterocycles identified (pyridine, 1H-pyrazole, and 
pyrimidine). Additional file 1: Figure S1 shows the most 
frequent heterocycles for the  A1R,  A2AR ligands, and 
PDE10A inhibitors and their relative frequencies in each 
set. It was found that they are furan, pyridine, xanthine, 
1H-pyrazole, pyrimidine, piperazine, and 9H-purine. All 
of these heterocycles ranked among the top 30 for  A1R, 
 A2AR ligands and PDE10A inhibitors. This indicated their 
suitability for designing multi-target ligands at these pro-
tein targets, given the overlap in chemical (heterocyclic) 
space. In the case where no percentage is displayed for 
a particular target, this means that the heterocycle does 
not appear among the top 30 for the set of compounds 
involved.
Designing new multi‑target ligands
A1R (2104),  A2AR (2489) and PDE10A inhibitors (679) 
consisting of the common and frequent heterocycles, 
were subjected to RECAP analysis/synthesis in MOE 
[26]. The RECAP function electronically fragments and 
recombines molecules based on chemical knowledge of 
11 chemical bond types derived from common chemical 
reactions [27]. As a result, 458,839 novel RECAP-derived 
compounds were formed. Finally the designed RECAP 
library was filtered using RDKit, Python according to 
the common and frequent heterocycles identified, which 
narrowed the list down to 22,233 compounds.
Target prediction
The SMILES of the designed RECAP library were stand-
ardized using the ChemAxon Command-Line Standard-
izer where the following options were selected: “Remove 
Fragment” (keep largest), “Neutralize”, “RemoveExplic-
itH”, “Clean2D”, “Mesomerize” and “Tautomerize” [56]. 
The standardized canonical SMILES were exported to 
CSV files, and subjected to enriched target prediction 
using PIDGIN 1.0 implementing the method devel-
oped by Liggi et al. [24, 31]. The target prediction for the 
designed RECAP library was performed using a recall 
probability threshold of 0.01 (which is a value consistent 
with greater confidence in the more positive predictions).
Enrichment calculations for the predicted targets of the 
designed RECAP library were performed to assess the 
likelihood of the active compounds against the targets of 
interest. In this procedure, the frequency of predicting 
 A1R,  A2AR and PDE10A targets for the designed RECAP 
library was compared with a background distribution of 
a diverse library covering a large chemical space and was 
assessed by two parameters: the estimation score and the 
average ratio. The cutoff selected for considering a target 
as sufficiently enriched required an estimation score less 
than or equal to 0.01 [31]. The statistical relevance of the 
prediction was assessed via a Chi squared test with yates 
correction in Scipy [32], using the contingency table of 
the RECAP library and background of randomly sampled 
PubChem compounds (Additional file 1: Figure S2).
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Receptor preparation
Docking with Glide [57] was performed against the 
human  A2AR protein crystal structure (PDB ID: 4EIY) 
bound to the antagonist ZM241385 and the PDE10A 
crystal structure (PDB ID: 4DDL) complexed with an 
inhibitor [33, 34]. Protein structures were prepared using 
the protein preparation wizard of maestro 9.3 [58], fol-
lowing the default protocol which accounts for energy 
refinement, hydrogen addition, pKa assignment, and 
side-chain rotational isomer refinement. Resolved water 
molecules were discarded, and the structure was cen-
tered using the co-crystallized ligand as the center of 
the receptor grid generated for each protein structure. 
The co-crystal structures of  A2AR with 4-{2-[(7-amino-
2-furan-2-yl[1, 2, 4]triazolo[1,5-a][1, 3, 5]triazin-5-yl)
amino]ethyl}phenol (PDB ID: 4EIY), and PDE10A with 
2-{1-[5-(6,7-dimethoxycinnolin-4-yl)-3-methylpyridin- 
2-yl]piperidin-4-yl}propan-2-ol (PDB ID: 4DDL), were 
selected as target structures.
The  A1R homology model (Additional file  2)  was con-
structed according to the method reported by Yaziji et al. 
[59–61], where the protein sequence of the human  A1R 
(accession number P30542) was aligned with the  A2AR 
template of PDB ID: 4EIY.
Ligand preparation
The entire set of 2563 ligands was prepared for docking 
with LigPrep 2.5 [62] using the default settings and the 
Epik option which introduces energy penalties associated 
with ionization and tautomerization [63].
Cut‑off generation for compound selection from docking 
models
In an attempt to validate the constructed  A2AR,  A1R, 
and PDE10A docking models, a set of known actives and 
inactives were docked against each target to ensure that 
they enriched actives. 81  A2AR receptor ligands reported 
in the literature were docked against the  A2AR model 
[64, 65]. For consistency 81 ChEMBL actives were also 
selected (for each of the  A1R and PDE10A proteins whose 
 Ki and  IC50 values are less than 10 µM), and these were 
docked against their respective target class. In addition, 
PubChem inactives (200 compounds) of each target class 
were docked.
A good separation was obtained for the medians of 
docking score distribution for actives versus inactives 
confirming that the actives are enriched. Additional 
file  1: Figure S5 shows the separation of the medians 
for the three docking models, −  6.93 (actives) ver-
sus −  5.64 (inactives) for the PDE10A docking model, 
−  7.66 (actives) versus −  6.01 (inactives) for the  A2AR 
docking model, and − 7.60 (actives) versus − 5.66 (inac-
tives) for the  A1R docking model. Statistical analysis 
was performed with R using a Mann–Whitney test [66] 
on the active and inactive docking score distributions of 
each target. The differences in medians were significant 
with p values < 0.05 (script provided in Additional file 1).
The  F1 score which is the harmonic mean of preci-
sion and recall, was computed (using a Python script, 
see Additional file  1) for all the docking scores of the 
ChEMBL actives and PubChem inactives for each model. 
A search was performed for a docking score threshold 
that gave the highest  F1 score, in order to perform sub-
structure analysis on compounds that were predicted as 
 A1R/A2AR–PDE10A multi-target ligands by target pre-
diction, and displayed docking scores that are lower than 
or equal to those with the highest  F1 score for each of 
the three docking models  (A1R,  A2AR, and PDE10A, see 
Additional files 3, 4, and 5). Furthermore, the thresholds 
found are intended to serve as reference scores for any 
structure-based design problem at these target classes.
Docking
The RECAP compounds that were predicted as  A1R/
A2AR–PDE10A multi-target ligands were docked against 
the  A2AR protein crystal structure (PDB ID: 4EIY) [33], 
the  A1R homology model and the PDE10A protein crys-
tal structure (PDB ID: 4DDL) [34] to investigate the 
molecular interactions. The Glide docking parameters 
used here are given in Additional file  1: Table S3. The 
parameters were deduced from docking experiments 
using known actives and inactives against each protein 
model.
Substructural analysis
Subsequently, substructure analysis was performed using 
DataWarrior 4.2.2, on the proposed  A1R/A2AR–PDE10A 
multi-target ligands predicted by both ligand-based and 
structure-based techniques (considering docking scores 
less than or equal to the threshold of the best F measure 
for each docking model). The chemical series found were 
[1,2,4] triazolo[1,5-c]quinazolines (50.4%), imidazo[1,5-
a]quinoxalines (14.4%), 6,7-alkoxyisoquinolines (10.6%), 
and 2-aminopyridine-3-carbonitriles (9.2%), in addi-
tion to various compounds consisting of the com-
mon and frequent heterocycles identified originally in 
the substructural analysis of the extracted ChEMBL 
compounds.
Synthesis of novel 4,6‑substituted 
2‑amino‑pyridin‑3‑carbonitriles
Due to both ease of the reaction and yield, a one-pot 
synthetic scheme was optimized for the purpose of syn-
thesizing 2-aminopyridine-3-carbonitriles. For the other 
series, the synthetic routes were multi-step reactions, 
which due to synthetic complexity are not reported here.
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The synthetic routes reported in the literature for the 
formation of derivatives of 6,7-alkoxyisoquinolines as 
selective PDE10A inhibitors involved multi-step reac-
tions ranging from 3 to 13 steps [67, 68]. Whereas, the 
procedures for the synthesis of the imidazo[1,5-a]quinox-
alines, known PDE10A inhibitors, consisted of 3–7 step 
reactions [69–72]. The [1,2,4]triazolo[1,5-c]quinazolines 
have been reported as potent and selective  A2AR antago-
nists and PDE10A inhibitors, and their synthesis involved 
4–7 step reactions [73–75].
Hence, given the fact that the 2-aminopyridine-3-car-
bonitriles were the only RECAP series that could be syn-
thesized via a one-pot synthetic scheme [37, 76, 77], we 
have selected these for synthesis and subsequent valida-
tion as multi-target ligands. In particular, we selected 
compounds, which did not exihibit any potential PAINs 
liability upon screening with the FAFDrug3 ADME-Tox 
Filtering Tool [40].
Chemistry
Unless otherwise indicated, all starting materials, reagents 
and solvents were purchased and used without further 
purification. After extraction from aqueous phases, the 
organic solvents were dried over anhydrous sodium sul-
fate. The reactions were monitored by thin-layer chro-
matography (TLC) on 2.5  mm Merck silica gel GF 254 
strips, and each of the purified compounds showed a 
single spot; unless stated otherwise, UV light and/or 
iodine vapor were used to detect compounds. The syn-
thesis of the target compounds was performed in coated 
Kimble vials on a PLS (6 ×  4) Organic Synthesizer with 
orbital stirring. Filtration and washing protocols for sup-
ported reagents were performed in a 12-channel vacuum 
manifold. The purity and identity of all tested compounds 
were established by a combination of HPLC, elemen-
tal analysis, mass spectrometry and NMR spectroscopy 
as described below. Purification of isolated products 
was carried out by column chromatography (Kieselgel 
0.040–0.063  mm, E. Merck) or medium pressure liquid 
chromatography (MPLC) on a CombiFlash Companion 
(Teledyne ISCO) with RediSep pre-packed normal-phase 
silica gel (35–60  µm) columns followed by recrystalliza-
tion. Melting points were determined on a Gallenkamp 
melting point apparatus and are uncorrected. The NMR 
spectra were recorded on Bruker AM300 and XM500 
spectrometers. Chemical shifts are given as δ values 
against tetramethylsilane as internal standard and J values 
are given in Hz. Mass spectra were obtained on a Varian 
MAT-711 instrument. Analytical HPLC was performed 
on an Agilent 1100 system using an Agilent Zorbax SB-
Phenyl, 2.1 mm ×  150 mm, 5 µm column with gradient 
elution using the mobile phases (A)  H2O containing 0.1% 
 CF3COOH and (B) MeCN and a flow rate of 1 mL/min. 
The purity of all tested compounds was determined to be 
greater than or equal to 95%.
The synthesis of the 4,6-substituted 2-amino-pyridin-
3-carbonitriles 1–25 was done via the one-pot synthetic 
route shown in Scheme  1. Varying both substituents 
on the ylidene malononitrile and the ketone reagents 
resulted in a variation of the substituents on positions 4 
and 6 of the pyridine ring.
Synthetic procedure
Substituted ylidene malononitrile (1.0  mmol), ketone 
(1.0  mmol) and ammonium acetate (5.0  mmol) in a 1:1 
toluene/EtOH mixture (7  mL) were stirred in a coated 
Kimble vial at 120  °C for 12–24  h. After reaction com-
pletion (TLC control), distilled water was added and the 
mixture was extracted with ethyl acetate (3  ×  10  mL). 
The organic phase was dried  (Na2SO4) and evaporated 
under reduced pressure to afford an oily residue that was 
purified by column chromatography using n-hexane-
ethyl acetate in 2:1 mixture.
2‑amino‑6‑(4‑fluorophenyl)‑4‑phenylpyridine‑3‑car‑
bonitrile (1) Purified by column chromatography 
(n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.246  g, 85% yield (97% purity by HPLC). 
MP 226–228  °C. 1H NMR (300  MHz, CDCl3), δ (ppm) 
8.08–7.95 (m, 2H), 7.69–7.58 (m, 2H), 7.60–7.47 (m, 3H), 
7.23–7.09 (m, 3H), 5.34 (s, 2H). MS (EI) m/z (%): 289.07 
 (M+, 100), 262.07 (7). Analysis calculated for  C18H12FN3: 
C, 74.73; H, 4.18; F, 6.57; N 14.52. Found: C, 74.70; H, 4.19; 
F, 6.55; N, 14.54.
2‑amino‑6‑(4‑hydroxy phenyl)‑4‑ phenylpy ri‑
dine‑3‑carbonitrile (2) Purified by column chroma-
tography (n-hexane-ethyl acetate 2:1) and then recrystal-
lized from EtOH to give 0.227 g, 79% yield (96% purity by 
HPLC). MP 241–243  °C. 1H NMR (300  MHz, CDCl3), δ 
(ppm) 9.92 (s, 1H), 7.99 (d, J = 8.6 Hz, 2H), 7.78–7.59 (m, 
2H), 7.58–7.47 (m, 3H), 7.15 (s, 1H), 6.88 (s, 2H), 6.83 (d, 
J = 8.7 Hz, 2H). MS (EI) m/z (%): 287.04  (M+, 100), 259.89 
(10). Analysis calculated for  C18H13N3O: C, 75.25; H, 4.56; 
N, 14.63; O, 5.57. Found: C, 75.27; H, 4.54; N, 14.62; O, 5.59.
2‑amino‑4‑phenyl‑6‑(1,3‑thiazol‑2‑yl)pyridine‑3‑car‑
bonitrile (3) Purified by column chromatography 
(n-hexane-ethyl acetate 2:1) and then recrystallized from 
EtOH to give 0.172 g, 62% yield (95% purity by HPLC). MP 
154–156 °C. 1H NMR (300 MHz, CDCl3), δ (ppm) 7.95 (d, 
J = 3.0 Hz, 1H), 7.72 (s, 1H), 7.66–7.65 (m, 2H), 7.52–7.50 
(m, 4H), 5.30 (s, 2H). MS (EI) m/z (%): 278.03  (M+, 100), 
276.97 (45). Analysis calculated for  C15H10N4S: C, 64.73; H, 
3.62; N, 20.13; S, 11.52. Found: C, 64.85; H, 3.48; N, 20.25; 
S, 11.42.
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2‑amino‑6‑(1‑methyl‑1H‑pyrrol‑2‑yl)‑4‑phenylpyr‑
idine‑3‑carbonitrile (4) Purified by column chroma-
tography (n-hexane-ethyl acetate 2:1) and then recrystal-
lized from EtOH to give 0.189 g, 69% yield (98% purity by 
HPLC). MP 152–153  °C. 1H NMR (300  MHz, CDCl3), δ 
(ppm) 7.67–7.54 (m, 2H), 7.56–7.42 (m, 3H), 7.30 (s, 1H), 
6.91 (s, 1H), 6.66–6.59 (m, 2H), 5.23 (s, 2H), 3.70 (s, 3H). 
MS (EI) m/z (%): 274.14  (M+, 100). Analysis calculated for 
 C17H14N4: C, 74.43; H, 5.14; N, 20.42. Found: C, 74.57; H, 
5.12; N, 20.30.
2‑amino‑4‑(2‑methoxy phenyl)‑6‑phenylpyri‑
dine‑3‑carbonitrile (5) Purified by column chroma-
tography (n-hexane-ethyl acetate 2:1) and then recrystal-
lized from EtOH to give 0.238 g, 79% yield (97% purity by 
HPLC). MP 199–200  °C. 1H NMR (300  MHz, CDCl3), 
δ (ppm) 8.03–7.93 (m, 2H), 7.52–7.41 (m, 4H), 7.31 (dd, 
J1 = 7.5 Hz, J2 = 1.8 Hz, 1H), 7.17 (s, 1H), 7.11–7.02 (m, 
2H), 5.27 (s, 2H), 3.88 (s, 3H). MS (EI) m/z (%): 301.16 
 (M+, 100), 270.12 (7), 120.10 (16.3). Analysis calculated for 
 C19H15N3O: C, 75.73; H, 5.02; N, 13.94; O, 5.31. Found: C, 
75.76; H, 5.04; N, 13.92; O, 5.33.
2‑amino‑4‑(2,4‑dimethoxyphenyl)‑6‑phenylpyri‑
dine‑3‑carbonitrile (6) Purified by column chroma-
tography (n-hexane–ethyl acetate 2:1) and then recrystal-
lized from EtOH to give 0.238 g, 72% yield (99% purity by 
HPLC). MP 155–157  °C. 1H NMR (300  MHz, CDCl3), δ 
(ppm) 8.02-7.90 (m, 2H), 7.52–7.38 (m, 3H), 7.32–7.22 (m, 
1H), 7.16 (s, 1H), 6.69–6.55 (m, 2H), 5.25 (s, 2H), 3.88 (s, 
3H), 3.86 (s, 3H). MS (EI) m/z (%): 331.14  (M+, 100), 165.51 
(9), 120.16 (11.3). Analysis calculated for  C20H17N3O2: C, 
72.49; H, 5.17; N, 12.68; O, 9.66. Found: C, 72.50; H, 5.19; N, 
12.71; O, 9.70.
2‑amino‑4‑(2H‑1,3‑benzodioxol‑5‑yl)‑6‑phenylpyr‑
idine‑3‑carbonitrile (7) Purified by column chroma-
tography (n-hexane-ethyl acetate 2:1) and then recrystal-
lized from EtOH to give 0.236 g, 75% yield (96% purity by 
HPLC). MP 220–221  °C. 1H NMR (300  MHz, CDCl3), δ 
(ppm) 8.12–7.86 (m, 2H), 7.56–7.38 (m, 3H), 7.20–7.08 (m, 
3H), 6.95 (d, J = 8.0 Hz, 1H), 6.06 (s, 2H), 5.33 (s, 2H). MS 
(EI) m/z (%): 315.11  (M+, 100), 157.52 (5). Analysis calcu-
lated for  C19H13N3O2: C, 72.37; H, 4.16; N, 13.33; O, 10.15. 
Found: C, 72.45; H, 4.06; N, 13.49; O, 10.00.
2‑amino‑4‑cyclohexyl‑6‑phenylpyridine‑3‑carboni‑
trile (8) Purified by column chromatography (n-hexane-
ethyl acetate 2:1) and then recrystallized from EtOH to give 
0.216 g, 78% yield (98% purity by HPLC). MP 125–126 °C. 
1H NMR (300 MHz,  CDCl3) δ (ppm): 7.95–7.92 (m, 1H), 
7.53–7.43 (m, 3H), 7.05 (s, 1H), 6.73 (s, 1H), 5.22 (s, 2H), 
2.90–2.85 (m, 2H), 1.90–1.78 (m, 4H), 1.52–1.39 (m, 4H), 
1.33–1.25 (m, 1H). MS (EI) m/z (%): 277.25  (M+, 74), 
246.15 (56), 222.15 (100). Analysis calculated for  C18H19N3: 
C, 77.95; H, 6.90; N, 15.15. Found: C, 78.03; H, 6.96; N, 
15.01.
2‑amino‑4‑cyclohexyl‑6‑(2‑f luorophenyl)pyri‑
dine‑3‑carbonitrile (9) Purified by column chroma-
tography (n-hexane-ethyl acetate 2:1) and then recrystal-
lized from EtOH to give 0.186 g, 63% yield (95% purity by 
HPLC). MP 126–127  °C. 1H NMR (300  MHz, CDCl3), 
δ (ppm) 7.89 (td, J = 7.8, 1.9 Hz, 1H), 7.47–7.31 (m, 1H), 
7.25–7.03 (m, 3H), 5.18 (s, 2H), 2.98–2.67 (m, 1H), 1.99–
1.73 (m, 5H), 1.53–1.16 (m, 5H). MS (EI) m/z (%): 295.15 
 (M+, 98.05), 263.05 (23.28), 251.00 (12), 240.00 (100). Anal-
ysis calculated for  C18H18FN3: C, 73.20; H, 6.14; F, 6.43; N, 
14.23. Found: C, 73.22; H, 6.17; F, 6.44; N, 14.25.
2‑amino‑4‑cyclohexyl‑6‑(2‑methylphenyl)pyri‑
dine‑3‑carbonitrile (10) Purified by column chroma-
tography (n-hexane-ethyl acetate 2:1) and then recrystal-
lized from EtOH to give 0.236 g, 81% yield (97% purity by 
HPLC). MP 120–121  °C. 1H NMR (300 MHz, CDCl3), δ 
(ppm) 7.73–7.10 (m, 4H), 6.71 (s, 1H), 5.20 (s, 2H), 2.95–
2.77 (m, 1H), 2.35 (s, 3H), 2.01–1.69 (m, 5H), 1.56–1.34 
(m, 4H), 1.34–1.18 (m, 1H). MS (EI) m/z (%): 291.14  (M+, 
100), 236.12 (48), 208.10 (91.7). Analysis calculated for 
 C19H21N3: C, 78.32; H, 7.26; N, 14.42. Found: C, 78.48; H, 
7.18; N, 14.34.
2‑amino‑4‑c yclohexyl‑6‑(thiophen‑2‑yl)pyri‑
dine‑3‑carbonitrile (11) Purified by column chroma-
tography (n-hexane-ethyl acetate 2:1) and then recrystal-
lized from EtOH to give 0.167 g, 59% yield (98% purity by 
HPLC). MP 160–162  °C. 1H NMR (300  MHz, CDCl3), 
δ(ppm) 7.63–7.62(m, 1H), 7.44 (d, J = 4.5 Hz, 1H), 7.12–
7.09 (m, 1H), 6.96 (s, 1H), 5.14 (s, 2H), 2.82–2.79 (m, 1H), 
1.90–1.78 (m, 5H), 1.55–1.43 (m, 4H), 1.30–1.19 (m, 1H). 
MS (EI) m/z (%): 283.04  (M+, 100), 251.99 (19), 228.02 (92). 
Analysis calculated for  C16H17N3S: C, 67.81; H, 6.05; N, 
14.83; S, 11.31. Found: C, 67.89; H, 6.13; N, 14.77; S, 11.21.
2‑amino‑4‑c yclohexyl‑6‑(thiophen‑3‑yl)pyri‑
dine‑3‑carbonitrile (12) Purified by column chroma-
tography (n-hexane-ethyl acetate 2:1) and then recrystal-
lized from EtOH to give 0.147 g, 52% yield (96% purity by 
HPLC). MP 145–146  °C. 1H NMR (300  MHz, CDCl3), 
δ(ppm) 7.94 (dd, J  =  3.0, 1.3  Hz, 1H), 7.59 (dd, J  =  5.1, 
1.3 Hz, 1H), 7.38 (dd, J = 5.1, 3.0 Hz, 1H), 6.93 (s, 1H), 5.14 
(s, 2H), 2.95–2.73 (m, 1H), 2.06–1.73 (m, 5H), 1.56–1.37 
(m, 4H), 1.38–1.19 (m, 1H). MS (EI) m/z (%):(%): 283.07 
 (M+, 100), 228.04 (93), 214.96 (52).Analysis calculated for 
 C16H17N3S: C, 67.81; H, 6.05; N, 14.83; S, 11.31. Found: C, 
67.91; H, 6.09; N, 14.67; S, 11.33.
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2‑amino‑4‑cyclohexyl‑6‑(furan‑2‑yl)pyridine‑3‑car‑
bonitrile (13) Purified by column chromatography 
(n-hexane-ethyl acetate 2:1) and then recrystallized 
from EtOH to give 0.174  g, 65% yield (98% purity by 
HPLC). MP 177–178  °C. 1H NMR (300  MHz, CDCl3), 
δ(ppm) 7.55 (dd, J = 1.7, 0.8 Hz, 1H), 7.06 (dd, J = 3.4, 
0.8 Hz, 1H), 7.03 (s, 1H), 6.54 (dd, J = 3.5, 1.8 Hz, 1H), 
5.15 (s, 2H), 3.01–2.68 (m, 1H), 2.04–1.74 (m, 5H), 
1.55–1.39 (m, 4H), 1.34–1.20 (m, 1H). MS (EI) m/z (%): 
267.11  (M+, 100), 212.02 (69). Analysis calculated for 
 C16H17N3O: C, 71.89; H, 6.41; N, 15.72; O, 5.98. Found: 
C, 71.91; H, 6.43; N, 15.71.
2‑amino‑6‑(2‑fluorophenyl)‑4‑(4‑methoxyphenyl)
pyridine‑3‑carbonitrile (14) Purified by column chro-
matography (n-hexane-ethyl acetate 2:1) and then recrys-
tallized from EtOH to give 0.188 g, 59% yield (97% purity 
by HPLC). MP 180–181 °C. 1H NMR (300 MHz, CDCl3), 
δ (ppm) 7.96 (td, J1 = 7.8, J2 = 1.9 Hz, 1H), 7.65–7.58 (m, 
2H), 7.47–7.37 (m, 1H), 7.31–7.23 (m, 2H), 7.23–7.09 (m, 
1H), 7.09–6.98 (m, 2H), 5.32 (s, 2H), 3.88 (s, 3H). MS (EI) 
m/z (%): 319.12  (M+, 100), 304.18 (12), 249.13 (16). Analy-
sis calculated for  C19H14FN3O: C, 71.46; H, 4.42; F, 5.95; N, 
13.16; O, 5.01. Found: C, 71.48; H, 4.44; F, 5.97; O, 5.05.
2‑amino‑4‑(4‑methoxyphenyl)‑6‑(2‑methylphenyl)
pyridine‑3‑carbonitrile (15) Purified by column chro-
matography (n-hexane-ethyl acetate 2:1) and then recrys-
tallized from EtOH to give 0.205 g, 65% yield (95% purity 
by HPLC). MP 151–152 °C. 1H NMR (300 MHz, CDCl3), 
δ (ppm) 7.61 (d, J = 8.3 Hz, 2H), 7.40 (d, J = 7.3 Hz, 1H), 
7.37–7.27 (m, 3H), 7.03 (d, J =  8.2  Hz, 2H), 6.86 (s, 1H), 
5.32 (s, 2H), 3.87 (s, 3H), 2.42 (s, 3H). MS (EI) m/z (%): 
314.10  (M+, 100), 271.06 (7), 208.11 (52). Analysis calcu-
lated for  C20H17N3O: C, 76.17; H, 5.43; N, 13.32; O, 5.07. 
Found: C, 76.31; H, 5.33; N, 13.52; O, 4.84.
2‑amino‑6‑(furan‑2‑yl)‑4‑(4‑methoxyphenyl)pyri‑
dine‑3‑carbonitrile (16) Purified by column chroma-
tography (n-hexane-ethyl acetate 2:1) and then recrystal-
lized from EtOH to give 0.198 g, 68% yield (99% purity by 
HPLC). MP 205–207  °C. 1H NMR (300  MHz,  CDCl3) δ 
(ppm): 7.65–7.54 (m, 3H), 7.16 (s, 1H), 7.11 (d, J = 3.5 Hz, 
1H), 7.03 (d, J  =  8.8  Hz, 2H), 6.62–6.51 (m, 1H), 5.30 
(s, 2H), 3.88 (s, 3H). MS (EI) m/z (%): 291.12  (M+, 100), 
145.63 (5). Analysis calculated for  C17H13N3O2: C, 70.09; 
H, 4.50; N, 14.42; O, 10.98. Found: C, 70.21; H, 4.38; N, 
14.68, O, 10.73.
2‑amino‑6‑(4‑hydroxyphenyl)‑4‑(4‑methoxyphenyl)
pyridine‑3‑carbonitrile (17) Purified by column chro-
matography (n-hexane- ethyl acetate 2:1) and then recrys-
tallized from EtOH to give 0.222 g, 70% yield (99% purity 
by HPLC). MP 248–250 °C. 1H NMR (300 MHz, CDCl3), 
δ (ppm) 9.89 (s, 1H), 7.98 (d, J  =  8.7  Hz, 2H), 7.61 (d, 
J  =  8.7  Hz, 2H), 7.11–7.06 (m, 3H), 6.84–6.81 (m, 4H), 
3.82 (s, 3H). MS (EI) m/z (%): 317.17  (M+, 100), 302.04 (6), 
158.50 (14). Analysis calculated for  C19H15N3O2: C, 71.91; 
H, 4.76; N, 13.24; O, 10.08. Found: C, 71.94; H, 4.79; N, 
13.25; O, 10.11.
2‑amino‑4,6‑bis(2‑fluorophenyl)pyridine‑3‑carbon‑
itrile (18) Purified by column chromatography (n-hex-
ane-ethyl acetate 2:1) and then recrystallized from EtOH 
to give 0.219 g, 73% yield (98% purity by HPLC). MP 180–
181  °C. 1H NMR (300  MHz, CDCl3), δ (ppm) 8.05–7.90 
(m, 1H), 7.56–7.41 (m, 2H), 7.33–7.06 (m, 6H), 5.34 (s, 2H). 
MS (EI) m/z (%): 307.06  (M+, 100), 279.99 (8). Analysis cal-
culated for  C18H11F2N3: C, 70.35; H, 3.61; F, 12.36, N, 13.67. 
Found: C, 70.37; H, 3.63; F, 12.33; N, 13.66.
2‑amino‑6‑(2‑fluorophenyl)‑4‑(2‑methoxyphenyl)
pyridine‑3‑carbonitrile (19) Purified by column chro-
matography (n-hexane-ethyl acetate 2:1) and then recrys-
tallized from EtOH to give 0.245 g, 78% yield (97% purity 
by HPLC). MP 187–188 °C. 1H NMR (300 MHz, CDCl3), 
δ (ppm) 7.97 (td, J = 7.8, 1.9 Hz, 1H), 7.52–7.35 (m, 2H), 
7.31 (td, J = 7.2, 1.5 Hz, 1H), 7.26–7.19 (m, 2H), 7.17–6.95 
(m, 3H), 5.27 (s, 2H), 3.88 (s, 3H). MS (EI) m/z (%): 319.12 
 (M+, 100), 290.14 (7), 138.01 (14). Analysis calculated for 
 C19H14N3FO: C, 71.46; H, 4.42; F, 5.95; N, 13.16; O, 5.01. 
Found: C, 71.44; H, 4.43; F, 5.92; O, 5.04.
2‑amino‑4‑(2‑methoxyphenyl)‑6‑(2‑methylphenyl)
pyridine‑3‑carbonitrile (20) Purified by column chro-
matography (n-hexane-ethyl acetate 2:1) and then recrys-
tallized from EtOH to give 0.186 g, 64% yield (98% purity 
by HPLC). MP 181–183  °C. 1H NMR (300 MHz,  CDCl3) 
δ (ppm): 7.47–7.40 (m, 2H), 7.32–7.28 (m, 4H), 7.09–7.02 
(m, 2H), 6.86 (s, 1H), 5.29 (s, 2H), 3.88 (s, 3H), 2.43 (s, 3H). 
MS (EI) m/z (%): 315.13  (M+, 100), 298.16 (12), 284.09 (18), 
208.10 (81.6). Analysis calculated for  C20H17N3O: C, 76.17; 
H, 5.43; N, 13.32; O, 5.07. Found: C, 76.19; H, 5.41; N, 13.36; 
O, 5.03.
2‑amino‑6‑(furan‑2‑yl)‑4‑(2‑methoxyphenyl)pyri‑
dine‑3‑carbonitrile (21) Purified by column chroma-
tography (n-hexane-ethyl acetate 2:1) and then recrystal-
lized from EtOH to give 0.244 g, 77% yield (96% purity by 
HPLC). MP 187–188  °C. 1H NMR (300  MHz,  CDCl3), δ 
(ppm): 7.55 (s, 1H), 7.44 (t, J = 8.1 Hz, 1H), 7.30 (dd, J = 7.4, 
1.7 Hz, 1H), 7.15–6.98 (m, 4H), 6.54 (dd, J = 3.3, 1.7 Hz, 
1H), 5.24 (s, 2H), 3.87 (s, 3H). MS (EI) m/z (%): 291.10  (M+, 
100), 262.14 (10). Analysis calculated for  C17H13N3O2: C, 
70.09; H, 4.50; N, 14.42; O, 10.98. Found: C, 70.11; H, 4.51; 
N, 14.41; O, 11.01.
Page 16 of 19Kalash et al. J Cheminform  (2017) 9:67 
2‑amino‑6‑(4‑hydroxyphenyl)‑4‑(2‑methoxyphenyl)
pyridine‑3‑carbonitrile (22) Purified by column chro-
matography (n-hexane-ethyl acetate 2:1) and then recrys-
tallized from EtOH to give 0.193 g, 60% yield (96% purity 
by HPLC). MP 210–212 °C. 1H NMR (300 MHz, DMSO-
d6), δ (ppm): 9.91 (s, 1H), 7.93 (d, J  =  9.0  Hz, 2H), 7.45 
(t, J = 7.8 Hz, 1H), 7.29 (dd, J = 7.4, 1.7 Hz, 1H), 7.16 (d, 
J = 8.3 Hz, 1H), 7.07 (d, J = 7.5 Hz, 1H), 7.03 (s, 1H), 6.82 
(d, J = 8.9 Hz, 2H), 6.77 (s, 2H), 3.77 (s, 3H). MS (EI) m/z 
(%): 317.13  (M+, 100), 300.09 (8), 286.11 (6).Analysis calcu-
lated for  C19H15N3O2: C, 71.91; H, 4.76; Cl, 13.24; O, 10.08. 
Found: C, 71.92; H, 4.74; Cl, 13.27; O, 10.05.
2‑amino‑4‑(2‑chlorophenyl)‑6‑(4‑hydroxyphenyl)
pyridine‑3‑carbonitrile (23) Purified by column chro-
matography (n-hexane-ethyl acetate 2:1) and then recrys-
tallized from EtOH to give 0.179 g, 59% yield (98% purity 
by HPLC). MP 215–217 °C. 1H NMR (300 MHz, DMSO-
d6), δ (ppm): 9.90 (s, 1H), 8.16–7.22 (m, 2H), 7.69–7.30 (m, 
4H), 7.16–6.50 (m, 5H). MS (EI) m/z (%): 320.99  (M+, 100), 
286.04 (5). Analysis calculated for  C18H12ClN3O: C, 67.19; 
H, 3.76; Cl, 11.02; N, 13.06; O, 4.97. Found: C, 67.37; H, 
3.94; Cl, 11.18; N, 12.88; O, 4.63.
2 ‑ a m i n o ‑ 4 , 6 ‑ b i s ( 4 ‑ h y d r o x y p h e n y l ) p y r i ‑
dine‑3‑carbo‑nitrile (24) Purified by column chroma-
tography (n-hexane–ethyl acetate 2:1) and then recrystal-
lized from EtOH to give 0.151 g, 53% yield (97% purity by 
HPLC). MP 299–300 °C. 1H NMR (300 MHz, DMSO-d6), 
δ (ppm) 9.92 (s, 2H), 8.19–7.79 (m, 2H), 7.68–7.37 (m, 
2H), 7.42–6.99 (m, 1H), 7.01–6.62 (m, 6H). MS (EI) m/z 
(%): 303.06  (M+, 100), 184.01 (6). Analysis calculated for 
 C18H13N3O2: C, 71.28; H, 4.32; N, 13.85; O, 10.55. Found: C, 
71.40; H, 4.54; N, 13.75; O, 10.31.
2‑amino‑4‑(furan‑2‑yl)‑6‑(thiophen‑3‑yl)pyri‑
dine‑3‑carbonitrile (25) Purified by column chromatog-
raphy (n-hexane-ethyl acetate 2:1) and then recrystallized 
from EtOH to give 0.123 g, 46% yield (95% purity by HPLC). 
MP 156–157 °C. 1H NMR (300 MHz,  CDCl3) δ(ppm): 8.01 
(dd, J = 3.0, 1.2 Hz, 1H), 7.66 (dd, J = 5.1, 1.2 Hz, 1H), 7.62 
(dd, J = 1.8, 0.6 Hz, 1H), 7.48 (dd, J = 3.6, 0.6 Hz, 1H), 7.45 
(s, 1H), 7.40 (dd, J = 5.1, 3.0 Hz, 1H), 7.40 (dd, J = 5.1, 3.0 Hz, 
1H), 6.61 (dd, J = 3.6, 1.8 Hz, 1H), 5.26 (s, 2H). MS (EI) m/z 
(%): 267.06  (M+, 100), 237.98 (6), 210.99 (7). Analysis calcu-
lated for  C14H9N3OS: C, 62.91; H, 3.39; N, 15.72; O, 5.99; S, 
11.99. Found: C, 63.11; H, 3.47; N, 15.58; O, 5.97; S, 11.87.
Pharmacological evaluation of novel 4,6‑substituted 
2‑amino‑pyridin‑3‑carbonitriles
Pharmacological evaluation was performed in a radioli-
gand binding competition assay, using  A1,  A2A,  A2B, and 
 A3 human receptors expressed in transfected CHO  (A1), 
HeLa  (A2A and  A3), and HEK-293  (A2B) according to the 
procedure reported by Bosch et al. [78].
 The activity measurements against the phosphodi-
esterases PDE7A, PDE7B, PDE9A and PDE10A were 
performed using AD293 cells that were transiently and 
separately transfected with human PDE7A, PDE7B, 
PDE9A, and PDE10A following the procedure described 
by Shipe et al. [43]. The  IC50 values were obtained by fit-
ting the data with non-linear regression using Prism 
2.1 software (GraphPad, San Diego, CA) [79], and the 
reported results are the mean of 3 experiments (n =  3) 
each performed in duplicate.
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